Summary
Genenta Science S.p.A. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Christopher C. Powers Farther Finance Advisors, LLC | 3 | $4.47 | $5.67 | $1.2 | 26.85% |
Genenta Science S.p.A. (GNTA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Genenta Science S.p.A. ever had a stock split?
Genenta Science S.p.A. Profile
| Biotechnology Industry | Healthcare Sector | Pierluigi Paracchi CEO | NASDAQ (CM) Exchange | 36870W100 CUSIP |
| IT Country | 13 Employees | - Last Dividend | - Last Split | 15 Dec 2021 IPO Date |
Overview
Genenta Science S.p.A. is a pioneering clinical-stage biotechnology company based in Italy, focusing on the development of innovative hematopoietic stem cell gene therapies aimed at treating solid tumors. Established in 2014 and having its headquarters in Milan, Genenta Science has made significant strides in the biotechnology field, particularly in gene therapy research. The company's mission revolves around exploiting the potential of gene manipulation in hematopoietic stem cells to create therapies that can effectively target and eliminate solid tumors, offering new hope for patients suffering from hard-to-treat cancers.
Products and Services
- Temferon
Genenta’s forefront product, Temferon, represents a cutting-edge development in the field of gene therapies for cancer treatment. Currently, in Phase 1/2a clinical trials, Temferon is designed for the treatment of glioblastoma multiforme in patients with an unmethylated MGMT gene promoter. This innovative therapy leverages the power of gene manipulation to target and destroy tumor cells, offering a novel approach in combating one of the most aggressive forms of brain cancer.
- Expansion into Other Solid Tumor Indications
Beyond glioblastoma multiforme, Genenta is exploring the potential of Temferon in treating other solid tumors. This includes locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. The expansion of Temferon's application showcases Genenta’s commitment to diversifying its therapeutic solutions, aiming to provide targeted and effective treatments for a broader range of solid tumors.
- Biologic Platform Development
Apart from Temferon, Genenta Science is developing a biologic platform tailored to deliver immunomodulatory molecules directly into tumors by exploiting monocytes/macrophages that infiltrate cancers. This innovative approach seeks to enhance the precision and efficacy of cancer treatment, by turning the tumor’s own environment against it. It represents a promising advancement in the fight against cancer, offering a novel strategy to bolster the body’s immune response against tumors.
